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Extraskeletal Ewing’s sarcoma is a rare soft tissue tumor that is morphologically indistinguishable from Ewing’s sarcoma of bone.
We report a case of extraskeletal Ewing’s sarcoma with several systemic problems. A 69-year-old man presented with a 5-month
history of a rapidly enlarging mass in the right thigh. Because preoperative radiotherapy with sanazole (AK-2123) contributed the
tumor mass reduction down to 40% in size, the tumor was successfully resected with clear surgical margins and repaired with a
musculocutaneous ﬂap. The high eﬃcacy of pre-operative low-dose radiotherapy with sanazole was histologically conﬁrmed that
the resected tumor specimen involved no viable tumor cells and showed 100% necrosis. Based on clinical outcomes in this case,
the combined modality of pre-operative low-dose radiotherapy with hypoxic cell radiosensitizer and adequate surgical resection
might provide for the useful clinical application of extraskeletal Ewing’s sarcoma treatment.
1.Introduction
Extraskeletal Ewing’s sarcoma (EES) is a rare type of Ewing’s
sarcoma that arises in the soft tissue at any location and is
nowregardedasamemberofafamilyofsmallcellneoplasms
of bone and soft tissue, including primitive neuroectodermal
tumors (PNETs) [1, 2]. Multimodal treatment combined
with surgical treatment, chemotherapy, and radiotherapy
(RT) contributes the improvements of clinical outcomes in
EES [3]. Deﬁnitive local control of Ewing’s sarcoma is a
prerequisite of cure and local failures are associated with an
extremely poor prognosis [4]. Although RT has been the
local treatment of choice in Ewing’s sarcoma, the clinical
impactonsurvivalbyRTiscontroversial[3,5].Postoperative
RT is mainly given in case of inadequate surgical margins or
poor response to chemotherapy [4]. However, the beneﬁts,
indication,andoptimaltimingofadjuvantRT(pre-operative
versus post-operative) remain unclear [6]. As compared with
post-operative RT, the relative advantages of pre-operative
RT include smaller and well-deﬁned treatment volume,
ability to use a lower dose, lack of tissue hypoxia, increased
tumor resectability, and improved limb function with less
late ﬁbrosis and edema [6].
Eﬃcacy of RT largely depends on tumor radiosensitivity
and the tolerance of normal tissues. To improve therapeutic
outcomes, RT is often combined with chemotherapeutic2 Sarcoma
Figure 1: Macroscopic ﬁndings of the tumor in the pre-treatment
condition. The tumor involved multiple ulcers and necrotic tissues.
Bar = 2cm.
drugs that are themselves cytotoxic and/or radiosensitizing.
Sanazole (AK-2123) as a radiosensitizer with irradiation in
various tumors showed encouraging results [7–9]. Here,
we describe a case of EES that were successfully treated
with surgical resection after pre-operative low-dose RT and
additional administration of sanazole as a hypoxic cell
radiosensitizer.
2.CaseReport
A 69-year-old man presented at our hospital with a 5-
month history of a rapidly enlarging mass in the right thigh.
His past history was pulmonary tuberculosis treated with
thoracoplasty and hepatitis C. Physical examination revealed
the presence of a large irregular mass with multiple ulcers
and necrotic tissues, measuring approximately 10 ×10cm in
the lateral side of the proximal thigh (Figure 1). Admission
laboratory data showed high levels of LDH, GOT, GPT, and
ALP, which are 643, 80, 39, and 441, respectively. Typical
tumor markers were within normal limits. A roentgenogram
of the right proximal thigh showed no apparent expansion to
the femur. Chest roentgenogram and computed tomography
showed no apparent metastatic lesion and no focus of
pulmonary tuberculosis. MR images demonstrated relatively
a well deﬁned and heterogeneous mass, which was attached
to the fascia lata and expanded across the skin layer (Figures
2(a), 2(b)). The signal intensity of the mass was isointense
to the adjacent skeletal muscles on T1-weighted images and
inhomogeneous hyperintense on T2-weighted images. The
mass was relatively well deﬁned and enhanced with Gd-
DTPA on STIR sequences (Figure 2(c)). However, partial
inﬁltrating expansions to subcutaneous tissues of the mass
made its margins unclear. Despite the mass contacted
with the compression to the tensor fascia lata muscle, the
gluteus maximus muscle, and the gluteus medius muscle,
no apparent signal intensity changes of muscles were seen.
Thallium-201 scintigrams showed a robust accumulation
accorded for the mass in both of early and delayed phases
(Figure 3). No other abnormal accumulation was detected.
Based on clinical ﬁndings and imaging characteristics,
the tumor was diagnosed as a primary soft tissue tumor
and an incisional biopsy was performed. Histopathology
of the permanent sections showed the nodular or sheets-
like proliferation pattern of small round cells with a high
nuclear/cytoplasmic ratio in the background of sparse extra-
cellular collagen (Figure 4). Immunohistochemistry of the
sections demonstrated that the staining of BCL2, MIC2,
CD56, O-13, neuron speciﬁc enolase (NSE), and synap-
tophysin were positive. They were negative for HMB-45,
S-100, broad cytokeratin (AE1/AE3 and MNF116), CD45,
CD79a, CD3, and CD20. In addition, the RT-PCR showed
the presence of EWS/FLI-1 fusion transcript from tumor
specimens. Together with the results of several examinations,
we diagnosed this tumor as EES.
Considering patient’s age, hepatic dysfunction, and
patient’s disagreement with chemotherapy, we precluded the
choice of the neoadjuvant chemotherapy. To deﬁne surgical
margins especially at subcutaneous tissues and to increase
tumor resectability, we determined to treat the patient with
pre-operative low-dose RT and additional administration of
sanazole before surgery [10]. As a result of the total dose
irradiationof30Gyin15fractionswithsanazole(0.6g/m2 ×
10 days), the tumor volume was reduced to approximately
40% of the pre-treatment condition (Figure 5). On thallium-
201 scintigrams, the accumulation of the tumor markedly
decreased in both of early and delayed phases. Subsequently,
we could perform the surgical resection with subtotal resec-
tion of the tensor fascia lata muscle, the gluteus maximus
muscle, the gluteus medius muscle, and adjacent soft tissues
to obtain wide surgical margins (Figure 6(a)). The huge
surgical defect in the lateral thigh was repaired with a
musculocutaneous ﬂap of rectus abdominis (Figure 6(b)).
There was no major complication in the perioperative
period. Histological examination of the resected tissue
demonstrated clear surgical margins. Because the tumor
cells completely showed necrotic appearances and there
were no viable tumor cells in the tumor specimen, we
diagnosedthenecrosisratioas100%(Figure 7).Basedonthe
histological ﬁndings, we could conﬁrm a high eﬃcacy of pre-
operative low-dose RT with sanazole in the present case. The
patient underwent follow-up without any local recurrence or
distant metastasis, and presented without any postoperative
functional disturbance for 24 months after surgery.
3. Discussion
EES is a tumor of unknown mesenchymal origin predom-
inantly aﬀecting men in the second and third decades of
life [2, 11]. The most frequent sites of occurrence are
the chest wall, lower extremities, and paravertebral region
[12]. Less frequently, the tumor occurs in the pelvis and
hip region, the retroperitoneum, and the upper extremities
[12]. Although EES is rare and very few data are avail-
able addressing optimal surgical and oncologic modalities,
EES should be considered in the diﬀerential diagnosis of
soft tissue tumor including embryonal rhabdomyosarcoma,
lymphoma, and neuroblastoma [1, 13]. EES and Ewing’sSarcoma 3
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Figure 2: MR images of the tumor in the pre-treatment condition. (a) Axial T1-weighted image. (b) Axial T2-weighted image. (c) Coronal
STIR sequence enhanced with Gd-DTPA. Bars = 2cm. The heterogeneous mass was attached to the fascia lata and expanded across the skin
layer.
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Figure 3: Thallium-201 scintigram of whole body in early phase.
Abnormal accumulations accorded for the mass were detected
(black arrows).
sarcoma of bone have similarities for natural history, histo-
logical ﬁndings, immunohistochemical staining results, and
molecularbiologicalcharacteristics[5,13].Thepatientswith
EES, like its osseous counterpart, should be treated with
the multimodal treatment including appropriate surgery,
multiagent chemotherapy and high-dose RT [13]. Raney
et al. reported a 10-year survival rate between 61%–77%
utilizing multiagent chemotherapy [14]. However, treatment
outcome after chemotherapy and RT has not yet been
determined [1, 5, 13–16]. Therefore, complete removal of
the tumor is essential whenever feasible. Complete resection
with wide surgical margins should remain the goal of
surgery because those patients who undergo a wide resection
can improve overall survival compared with those patients
treated with inadequate surgical margins or without surgical
resection [5].
Despite the role of RT in the management of bone
sarcoma is limited, its primary application appears to be
in Ewing’s sarcoma [6]. The importance of systemic treat-
ment by chemotherapy and its histological responses as a
prognostic factor for outcome has been recognized for some
time [3, 4]. However, several large series demonstrate that
improvement in local control has been the major route to
improvedoutcomesinEwing’ssarcomaincludingEEF[3].In
the patients with unfavorable locations (e.g., spine, pelvis) or
large residual tumors after induction chemotherapy, the risk
of local failures is high after surgery alone because adequate
resection is diﬃcult to achieve [3, 17]. The addition of post-
operative RT in these patients has resulted in improved
rates of local control and survival outcomes [3]. Current
consensus favors the use of post-operative RT in all patients
with inadequate surgical margins and/or poor responder
to chemotherapy [3, 6]. On the other hand, there is no
diﬀerence between pre-operative RT and post-operative RT
in local control, distant control, or survival rates despite the
incidence of wound complications is higher in pre-operative
RT than in post-operative RT [6]. When a negative surgical4 Sarcoma
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Figure 4: Histological ﬁndings of the HE-stained biopsy sections. (a) Low power view (magniﬁcation: x6). Cellular nodules are scatters
within ﬁbrous stroma. (b) High power view (magniﬁcation: x36). The tumor cells have oval nuclei with scant cytoplasms. Mitotic ﬁgures are
common.
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Figure 5: The tumor mass reduction induced by pre-operative RT. (a) Macroscopic ﬁndings of the tumor. (b) Coronal STIR sequence
enhanced with Gd-DTPA. Bars = 2cm. The size of the tumor reduced to approximate 40% of the pre-treatment condition.
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Figure 6: (a) Macroscopic ﬁndings of the resected tumor with adjacent soft tissues. Note that the specimen was longitudinally dissected
across the tumor (white arrow). (b) Post-operative ﬁndings repaired with a musculocutaneous ﬂap of rectus abdominis.Sarcoma 5
Figure 7: Histological ﬁndings of the HE-stained resected sections
(magniﬁcation: x36). The tumor cells completely showed necrotic
appearances.
margin is obtained following pre-operative RT, local failure
rates are comparable with those achieved with negative
margin surgery [17]. Therefore, pre-operative RT could
be an attractive application to avoid inadequate surgical
margins in case of large tumors or tumors in unfavorable
locations. In addition, RT with hypoxic cell radiosensitizer is
often used to improve therapeutic outcomes [18]. Sanazole
(AK-2123) was presented as a new type of hypotoxic cell
radiosensitizer owing to its low-toxicity (e.g., reversible
peripheral neuropathy) and high-radiosensitizing eﬀects and
hasbeentestedclinicallyinvarioustumors[7,18].Following
these reports, the present case with large EES underwent pre-
operative RT with 30Gy and additional administration of
sanazole to increase the tumor resectability. Despite the total
dose of radiation in post-operative RT depends on the extent
of resection, the relevant dose of pre-operative RT avoiding
complications remains unclear. The recommended radiation
doses are 55.8Gy for gross residual disease and 50.4Gy for
microscopicdiseaseaftersurgicalresection[19].Considering
the higher risk of acute wound healing complications in
pre-operative RT, we determined to deliver the total dose
of 30Gy in 15 fractions which is relatively low dose [16,
20, 21]. Consequently, we could achieve the tumor size
reduction to 40% of the pre-treatment condition and obtain
the clear surgical margin without any complications. The
best threshold for the extent necrosis for the addition of
post-operativeRTisyetunknown.However,thelocalcontrol
rates with more than 90% necrosis seem low enough for
omittingRT[3].Fromthemicroscopicresultsoftheresected
specimen with 100% necrosis, we omitted the addition of
post-operative RT in the present case.
Despite the limitation of this case including its short
follow-up period, our clinical outcomes in radiosensitive
EES suggested the high eﬃcacy of pre-operative low-dose
RT with sanazole. Therefore, the combined modality of pre-
operative low-dose RT with hypoxic cell radiosensitizer and
adequate surgical resection might provide for the useful
clinical application of EES treatment.
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